PerkinElmer to buy Immunodiagnostic Systems

By staff writers

May 17, 2021 -- PerkinElmer announced it will acquire U.K. firm Immunodiagnostic Systems Holdings (IDS) for approximately $155 million. PerkinElmer said the deal will enable the company to grow its overall diagnostics business, specifically its immunodiagnostics segment.

The combination will also enable PerkinElmer to combine its channel expertise and testing capabilities with IDS's chemiluminescence products in endocrinology, autoimmunity, and infectious diseases, the firm added. The deal is expected to close early in the third quarter of 2021, subject to approvals from the shareholders.

Financially, PerkinElmer said the addition of the IDS business will result in a compound annual growth rate of high single digits over the next few years.

Euroimmun launches new diagnostic microscope
PerkinElmer subsidiary Euroimmun has released EuroPattern Microscope Live, a compact immunofluorescence microscope available with the fourth generation...
PerkinElmer unveils COVID-19 rapid antigen test
PerkinElmer has launched a lateral-flow immunoassay COVID-19 antigen test, a rapid antigen test suitable for mass COVID-19 screening or for diagnosis...
FDA clears PerkinElmer coronavirus test for asymptomatic use
PerkinElmer's New Coronavirus Nucleic Acid Detection kit has received an emergency use authorization from the U.S. Food and Drug Administration (FDA)...
PerkinElmer to buy Oxford Immunotec Global
PerkinElmer plans to acquire Oxford Immunotec Global and that company's infectious disease testing technology in a deal worth $591 million. The purchase...
Euroimmun debuts new ELISA SARS-COV-2 antigen test
PerkinElmer subsidiary Euroimmun has launched a SARS-CoV-2 antigen enzyme-linked immunosorbent (ELISA) assay that can detect the proteins from the virus.

Copyright © 2021

Last Updated ls 5/17/2021 1:33:01 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current